Antibodies  ||| S:0 E:11 ||| NNS
as  ||| S:11 E:14 ||| IN
an  ||| S:14 E:17 ||| DT
unlimited  ||| S:17 E:27 ||| JJ
source  ||| S:27 E:34 ||| NN
of  ||| S:34 E:37 ||| IN
anti-infective ||| S:37 E:51 ||| NNP
,  ||| S:51 E:53 ||| ,
anti-tumour  ||| S:53 E:65 ||| JJ
and  ||| S:65 E:69 ||| CC
immunomodulatory  ||| S:69 E:86 ||| FW
peptides  ||| S:86 E:95 ||| FW
Antibodies  ||| S:95 E:106 ||| FW
( ||| S:106 E:107 ||| -LRB-
Abs ||| S:107 E:110 ||| NNP
)  ||| S:110 E:112 ||| -RRB-
are  ||| S:112 E:116 ||| VBP
emerging  ||| S:116 E:125 ||| VBG
as  ||| S:125 E:128 ||| IN
an  ||| S:128 E:131 ||| DT
important  ||| S:131 E:141 ||| JJ
class  ||| S:141 E:147 ||| NN
of  ||| S:147 E:150 ||| IN
therapeutic  ||| S:150 E:162 ||| JJ
agents  ||| S:162 E:169 ||| NNS
for  ||| S:169 E:173 ||| IN
the  ||| S:173 E:177 ||| DT
treatment  ||| S:177 E:187 ||| NN
of  ||| S:187 E:190 ||| IN
various  ||| S:190 E:198 ||| JJ
human  ||| S:198 E:204 ||| JJ
diseases ||| S:204 E:212 ||| NNS
,  ||| S:212 E:214 ||| ,
often  ||| S:214 E:220 ||| RB
conjugated  ||| S:220 E:231 ||| VBN
to  ||| S:231 E:234 ||| TO
drugs  ||| S:234 E:240 ||| NNS
or  ||| S:240 E:243 ||| CC
toxic  ||| S:243 E:249 ||| JJ
substances ||| S:249 E:259 ||| NNS
.  ||| S:259 E:261 ||| .
In  ||| S:261 E:264 ||| IN
recent  ||| S:264 E:271 ||| JJ
years ||| S:271 E:276 ||| NNS
,  ||| S:276 E:278 ||| ,
the  ||| S:278 E:282 ||| DT
incidence  ||| S:282 E:292 ||| NN
of  ||| S:292 E:295 ||| IN
cancer  ||| S:295 E:302 ||| NN
and  ||| S:302 E:306 ||| CC
infectious  ||| S:306 E:317 ||| JJ
diseases  ||| S:317 E:326 ||| NNS
has  ||| S:326 E:330 ||| VBZ
increased  ||| S:330 E:340 ||| VBN
dramatically  ||| S:340 E:353 ||| RB
making  ||| S:353 E:360 ||| VBG
it  ||| S:360 E:363 ||| PRP
imperative  ||| S:363 E:374 ||| VBP
to  ||| S:374 E:377 ||| TO
discover  ||| S:377 E:386 ||| VB
new  ||| S:386 E:390 ||| JJ
effective  ||| S:390 E:400 ||| JJ
therapeutic  ||| S:400 E:412 ||| JJ
molecules ||| S:412 E:421 ||| NNS
.  ||| S:421 E:423 ||| .
Among  ||| S:423 E:429 ||| IN
these ||| S:429 E:434 ||| DT
,  ||| S:434 E:436 ||| ,
small  ||| S:436 E:442 ||| JJ
peptides  ||| S:442 E:451 ||| NNS
are  ||| S:451 E:455 ||| VBP
arousing  ||| S:455 E:464 ||| VBG
great  ||| S:464 E:470 ||| JJ
interest ||| S:470 E:478 ||| NN
.  ||| S:478 E:480 ||| .
Synthetic  ||| S:480 E:490 ||| JJ
peptides ||| S:490 E:498 ||| NN
,  ||| S:498 E:500 ||| ,
representative  ||| S:500 E:515 ||| NN
of  ||| S:515 E:518 ||| IN
variable  ||| S:518 E:527 ||| NN
and  ||| S:527 E:531 ||| CC
constant  ||| S:531 E:540 ||| JJ
region  ||| S:540 E:547 ||| NN
fragments  ||| S:547 E:557 ||| NNS
of  ||| S:557 E:560 ||| IN
Abs ||| S:560 E:563 ||| NNP
,  ||| S:563 E:565 ||| ,
were  ||| S:565 E:570 ||| VBD
proved  ||| S:570 E:577 ||| VBN
to  ||| S:577 E:580 ||| TO
exert  ||| S:580 E:586 ||| VB
in  ||| S:586 E:589 ||| IN
vitro ||| S:589 E:594 ||| NN
,  ||| S:594 E:596 ||| ,
ex  ||| S:596 E:599 ||| FW
vivo  ||| S:599 E:604 ||| FW
and ||| S:604 E:607 ||| CC
/ ||| S:607 E:608 ||| NNP
or  ||| S:608 E:611 ||| CC
in  ||| S:611 E:614 ||| IN
vivo  ||| S:614 E:619 ||| JJ
anti-microbial ||| S:619 E:633 ||| NN
,  ||| S:633 E:635 ||| ,
anti-viral ||| S:635 E:645 ||| NNP
,  ||| S:645 E:647 ||| ,
anti-tumour  ||| S:647 E:659 ||| JJ
and ||| S:659 E:662 ||| CC
/ ||| S:662 E:663 ||| NNP
or  ||| S:663 E:666 ||| CC
immunomodulatory  ||| S:666 E:683 ||| JJ
activities ||| S:683 E:693 ||| NNS
,  ||| S:693 E:695 ||| ,
mediated  ||| S:695 E:704 ||| VBG
by  ||| S:704 E:707 ||| IN
different  ||| S:707 E:717 ||| JJ
mechanisms  ||| S:717 E:728 ||| NNS
of  ||| S:728 E:731 ||| IN
action  ||| S:731 E:738 ||| NN
and  ||| S:738 E:742 ||| CC
regardless  ||| S:742 E:753 ||| RB
of  ||| S:753 E:756 ||| IN
the  ||| S:756 E:760 ||| DT
specificity  ||| S:760 E:772 ||| NN
and  ||| S:772 E:776 ||| CC
isotype  ||| S:776 E:784 ||| NN
of  ||| S:784 E:787 ||| IN
the  ||| S:787 E:791 ||| DT
Ab ||| S:791 E:793 ||| NNP
.  ||| S:793 E:795 ||| .
Some  ||| S:795 E:800 ||| DT
of  ||| S:800 E:803 ||| IN
these  ||| S:803 E:809 ||| DT
synthetic  ||| S:809 E:819 ||| JJ
peptides  ||| S:819 E:828 ||| NNS
possess  ||| S:828 E:836 ||| VBP
the  ||| S:836 E:840 ||| DT
ability  ||| S:840 E:848 ||| NN
to  ||| S:848 E:851 ||| TO
spontaneously  ||| S:851 E:865 ||| VB
and  ||| S:865 E:869 ||| CC
reversibly  ||| S:869 E:880 ||| JJ
self-assemble  ||| S:880 E:894 ||| NN
in  ||| S:894 E:897 ||| IN
an  ||| S:897 E:900 ||| DT
organised  ||| S:900 E:910 ||| JJ
network  ||| S:910 E:918 ||| NN
of  ||| S:918 E:921 ||| IN
fibril-like  ||| S:921 E:933 ||| JJ
structure ||| S:933 E:942 ||| NN
.  ||| S:942 E:944 ||| .
Ab  ||| S:944 E:947 ||| NNP
fragments  ||| S:947 E:957 ||| NNS
may  ||| S:957 E:961 ||| MD
represent  ||| S:961 E:971 ||| VB
a  ||| S:971 E:973 ||| DT
novel  ||| S:973 E:979 ||| NN
model  ||| S:979 E:985 ||| NN
of  ||| S:985 E:988 ||| IN
targeted  ||| S:988 E:997 ||| JJ
anti-infective  ||| S:997 E:1012 ||| JJ
and  ||| S:1012 E:1016 ||| CC
anti-tumour  ||| S:1016 E:1028 ||| JJ
auto-delivering  ||| S:1028 E:1044 ||| JJ
drugs ||| S:1044 E:1049 ||| NNS
.  ||| S:1049 E:1051 ||| .
